ft 22 apr 93 survey pharmaceut research develop 5 work togeth creat new product research develop market depart need focu resourc research develop cost increas need focu resourc becom ever greater r amp depart must join market depart match scientif expertis market opportun said dr trevor jone wellcom director research develop medic uk market pressur world pharmaceut compani find effect new drug increas accord us pharmaceut manufactur associ us industri spend dollar 12 6bn worldwid r amp achiev 15 per cent return invest minimum compani might expect given risk 10 per cent per annum compound growth sale current dollar 231bn demand downward price pressur compani like long term winner increasingli aggress competit r amp environ effect r amp manag make full use new technolog discov new compound utilis skill market depart earli stage concept idea one compani wellcom believ success pharmaceut compani depend fundament qualiti r amp market activ interact synergi three phase involv develop product accord dr jone requir good commerci input becom quantifi import phase progress good exampl market r amp work togeth 5 lipoxygenas inhibitor said dr jone lipoxygenas pathway gener respons inflammatori disord known involv inflamm whether inflammatori bowel asthma allerg rhiniti psoriasi arthriti dr jone question focu product inflammatori condit drug work earli stage want market depart focu attent area like one go otherwis shotgun therapi need someon work agre togeth focu beyond discoveri first phase said asthma big pathway first task go volunt see work get phase ii need market depart give design busi case go start spend pound 50m pound 100m goal chang consider past five 10 year said dr jone drug go make wellcom pound 50m year three go dr rolf kreb chairman boehring ingelheim former head bayer r amp said boehring ingelheim problem choos compound current process set test properli function develop process need go big market go nich indic peopl formerli fear go small market zero therapi know size market depend econom countri sever diseas make look market develop differ way dr kreb point total cost dollar 200m includ failur divid success realis compet highli competit market need high therapeut standard need far market take three nine year establish drug lower therapeut standard complet new product need less market may well allow profit nich market chang technolog open nich market new drug may accept futur indic high therapeut benefit get higher price lower promot cost could make nich attract boehring ingelheim futur look medic properti compound decid area interest may wide rang compound told market peopl could happen organis market longer stabl function said dr kreb may jump indic indic view taken ciba geigi work area unmet medic need room improv intern know dr max wilhelm pierr douaz head pharmaceut ciba said necessarili market expertis market realli build expertis target sfr300m five year drug question develop said figur us dollar 250m otherwis licens product especi product aim gener practition would stretch market resourc astra therapeut area chosen said dr clae wilhelmsson execut vice presid r amp develop medicin chose us scienc lead us compet develop go start area field astra prepar adopt area three year ago compani cancer isinto immuno suppressor taken respiratori field cancer look medicin therapeut need tri develop complet new idea rather compound exampl develop ace inhibitor licens one hoechst said alan archer editor financi time pharmaceut busi news